Investing.com - Leerink Partners downgraded Gossamer Bio Inc. (NASDAQ:GOSS) to Market Perform from Outperform on Tuesday and lowered its price target to $1.00 from $6.00. The stock plunged 80% in the ...
The drug was generally well tolerated, with treatment-emergent adverse events reported in 86.5% of patients receiving seralutinib versus 80.5% on placebo. Cough was the most frequently reported ...
Gossamer Bio Inc. GOSS dropped during early trading on Monday after the company shared topline results from the Phase 3 PROSERA study evaluating seralutinib in pulmonary arterial hypertension. PAH is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results